An increasingly broad spectrum of neurological disorders have been associated with voltage gated potassium channel (VGKC)-complex antibodies, including peripheral nerve hyperexcitability, Morvan's syndrome, limbic encephalitis, epilepsy and, more recently, idiopathic pain and psychiatric disorders. Over the past several years, there have been great leaps in our understanding of VGKC autoimmunity, including identification of specific antigenic targets in VGKC associated proteins.1 ,2 Several specific targets of VGKC-complex associated antibodies have now been identified, including the cell surface antigens leucine-rich glioma inactivated 1 (LGI1) and contactin associated protein 2 (CASPR2).1 ,2 Antibodies to LGI1 are associated with predominantly …